- Home
- Products
KYPROLIS (Carfilzomib)
KYPROLIS (Carfilzomib)
- Medicine Name: Kyprolis
- Generic Name: Carfilzomib
- Dosage Form & Strength: For Injection – 10 mg, 30 mg, and 60 mg lyophilized powder in single-dose vials
- Manufactured By: Amgen Inc.
- FDA Approval: July 20, 2012
Kyprolis (carfilzomib) is a proteasome inhibitor used for the treatment of adults with relapsed or refractory multiple myeloma (RRMM). It is indicated for patients who have received one to three prior lines of therapy.
Kyprolis may be used:
- In combination with lenalidomide and dexamethasone (KRd)
- In combination with daratumumab and dexamethasone (DKd)
- With daratumumab and hyaluronidase-fihj and dexamethasone
- With isatuximab and dexamethasone (Isa-Kd)
- As monotherapy in certain cases
Cardiac Toxicity: May cause serious heart problems including heart failure and arrhythmias. Monitor patients with cardiovascular history.
Renal Toxicity: Regular monitoring of kidney function is essential. Dose modification may be required in cases of renal impairment.
Tumor Lysis Syndrome (TLS): Risk of TLS exists. Ensure proper hydration and electrolyte monitoring.
Pulmonary Toxicity: May lead to pulmonary fibrosis or pneumonitis. Prompt evaluation for respiratory symptoms is advised.
Hypertension: Monitor blood pressure regularly and treat high readings according to clinical guidelines.
Thrombosis Risk: Increased risk of blood clots. Patients should watch for signs like leg swelling or chest pain.
Infusion Reactions: Fever, chills, and rash may occur. Premedication with dexamethasone is often advised.
Myelosuppression: Risk of thrombocytopenia, neutropenia, and anemia. Regular blood counts are required.
Reproductive Risk: Carfilzomib can harm an unborn baby. Avoid use during pregnancy and breastfeeding. Use effective contraception.
To import Kyprolis (Carfilzomib) into India, the following are required:
- A valid prescription from a qualified oncologist
- Patient’s diagnostic reports
- Government-issued ID proof of the patient
Order Process:
Orders are confirmed only after receipt of complete documentation and applicable import permits.
Availability in India:
Kyprolis is not commercially available at Indian retail pharmacies. GlobalRareMeds facilitates access under the Named Patient Import Program, sourcing from globally approved suppliers.
GlobalRareMeds sources Kyprolis (Carfilzomib) from authorized manufacturers and suppliers in USA, Canada, and Europe.
Deliveries are processed through our fulfillment center in Ambernath, Thane District, covering all major cities including Mumbai, Delhi, Bengaluru, Hyderabad, Pune, Chennai, Kolkata, Ahmedabad, Jaipur, and more.
Contact us to place your order:
📧 info@globalraremeds.com
📞 +91-99675 15602
📱 WhatsApp: +91-99675 15602
What is the generic name of Kyprolis®?
Carfilzomib.
Who manufactures Kyprolis®?
Amgen Inc.
Is Kyprolis® FDA approved?
Yes, Kyprolis was approved by the U.S. FDA on July 20, 2012.
What are the dosage forms of Kyprolis®?
Kyprolis is available in 10 mg, 30 mg, and 60 mg lyophilized powder for injection (IV use).
What are the common side effects of Kyprolis®?
- As monotherapy: anemia, fatigue, diarrhea, nausea, dyspnea, pyrexia
- In combination: hypertension, upper respiratory infections, thrombocytopenia, insomnia, cough
How should Kyprolis be stored?
Store vials between 2°C to 8°C. Keep in original packaging to protect from light.
Can I legally import Kyprolis to India?
Yes, Kyprolis can be imported under the Named Patient Program with a valid doctor’s prescription and documentation.
Is Kyprolis available in SAARC & Gulf countries?
Yes. GlobalRareMeds can support delivery to Nepal, Sri Lanka, Bangladesh, Bhutan, UAE, Qatar, and more.
Is there a generic version of Kyprolis available?
Yes, Carfilnat (Carfilzomib 60 mg injection) is an Indian generic version. GlobalRareMeds can help you access either the branded or generic version based on doctor recommendation.
How do I get the best price for Kyprolis in India?
For accurate pricing and procurement assistance, reach out via:
📧 info@globalraremeds.com
📞 +91-99675 15602
Contact Patient Support
If you have questions about your order, need assistance with documentation, or require support with medicine availability, our GlobalRareMeds Patient Support Team is here to help. We aim to respond within 24 hours, Monday to Friday, between 9:00 AM and 10:00 AM IST.
info@globalraremeds.com
Phone
+91 99675 15602
+91 99675 15602
Disclaimer
All trademarks, brands, and product names featured on this website are the property of their respective owners. GlobalRareMeds does not claim ownership or affiliation unless explicitly stated. Our role is to provide reliable and transparent access to difficult-to-source medicines through named-patient import services, based on valid prescriptions and legal requirements.
The product-related content on this website is shared to the best of our knowledge, compiled from publicly available sources and regulatory documents. However, GlobalRareMeds does not guarantee the accuracy, completeness, or timeliness of this information. We strongly recommend that all medical decisions, including usage and dosage, be made only in consultation with the prescribing doctor. GlobalRareMeds assumes no responsibility for consequences arising from reliance on this information without appropriate medical guidance
